ARS Pharmaceuticals
SPRY
70 hedge funds and large institutions have $94.7M invested in ARS Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 21 increasing their positions, 28 reducing their positions, and 16 closing their positions.
6,167% more call options, than puts
Call options by funds: $188K | Put options by funds: $3K
3% less funds holding
Funds holding: 72 → 70 (-2)
9% less ownership
Funds ownership: 85.81% → 76.81% (-9%)
13% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 16
25% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 28
53% less capital invested
Capital invested by funds: $200M → $94.7M (-$106M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$5.23M |
| 2 |
Renaissance Technologies
New York
|
+$1.32M |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
+$1.18M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$1.05M |
| 5 |
Two Sigma Advisers
New York
|
+$627K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$11.6M |
| 2 |
Morgan Stanley
New York
|
-$4.38M |
| 3 |
Millennium Management
New York
|
-$3.96M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
-$3.18M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.13M |
SPRY Hedge Fund Activity: Q1 2022 in Review
70 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in ARS Pharmaceuticals (SPRY) for Q1 2022, worth a combined $94.7M — down 53% from $200M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of SPRY and 14 opened new positions — a net loss of 2 holders — while 28 trimmed existing stakes and 21 added.
The largest buyer was Wasatch Advisors, adding an estimated $5.23M. The largest seller was RA Capital Management, exiting entirely with an estimated $11.6M sold.
- 70 institutional investors held ARS Pharmaceuticals (SPRY) as of Q1 2022, down from 72 in Q4 2021.
- Funds reported $94.7M of ARS Pharmaceuticals stock for Q1 2022, down 53% quarter-over-quarter.
- 14 funds opened new ARS Pharmaceuticals positions in Q1 2022 and 16 closed out, a net change of -2 holders.
- The largest ARS Pharmaceuticals buyer in Q1 2022 was Wasatch Advisors, an estimated $5.23M added.
- The largest ARS Pharmaceuticals seller in Q1 2022 was RA Capital Management, an estimated $11.6M sold.
Based on aggregated 13F filings for Q1 2022.